Zydus Lifesciences gains on launching Nivolumab biosimilar ‘Tishtha’ in India
Zydus Lifesciences is currently trading at Rs. 885.50, up by 9.40 points or 1.07% from its previous closing of Rs. 876.10 on the BSE.
The scrip opened at Rs. 879.95 and has touched a high and low of Rs. 888.25 and Rs. 876.55 respectively. So far 10204 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 890.00 and Rs. 856.00 respectively. The current market cap of the company is Rs. 88951.08 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.85% respectively.
Zydus Lifesciences has launched the world’s first biosimilar of Nivolumab in India under the brand name Tishtha to treat multiple cancers, reinforcing the company’s growing capability in advanced biologics and Immuno-Oncology. Tishtha will be available in 100 mg and 40 mg dosages priced at Rs 28,950 and Rs 13,950 respectively. The prices are around 1/4th of the reference drug. This will improve affordability and reduce the overall treatment burden for patients. The two-strength portfolio enables oncologists to optimise dosing and minimise wastage - a key driver of treatment economics in immunotherapy.
Developed and manufactured in India, Tishtha ensures long-term dependability for patients throughout their treatment journey. For patients living with cancer, sustained and predictable access to therapy is critical. By introducing Tishtha in India, the company expands access to advanced Immuno-Oncology treatment.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
